

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human IFN-alpha 2/IFNA2 in ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) IFNE, rhIFNB, rhIFNG, or recombinant cotton rat IFNA is observed. In sandwich ELISAs, less than 8% cross-reactivity with rhIFNA-7, rhIFNA-8,
Source	Monoclonal Mouse IgG ₁ Clone # 967314
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Human embryonic kidney cell line HEK-293-derived transfected with human IFN-alpha 2/IFNA2 Met1-Glu188 Accession # P01563
Conjugate	Alexa Fluor 700 Excitation Wavelength: 675-700 nm Emission Wavelength: 723 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Immunocytochemistry Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Interferon-alpha 2 (IFNA2), also known as leukocyte interferon, is a type I interferon produced by macrophages, CD8 resting T cells, tonsillar NK cells, germinal center B cells, as well as epithelial cells, tumor cells and melanocytes. IFN alpha has at least nine different isoforms.

IFNA2 is a ligand for a cell surface receptor with two subunits, IFN-alpha R2 (ligand binding) and IFN-alpha R1 (ligand binding and signal transduction). IFNA2 has both antiviral and immunomodulatory activities on target cells. Intranasal administration has been shown to reduce viral load in subjects with the common cold. While IFNA2 is a prognostic factor for hepatocellular carcinoma, Interferon alpha 2b, has been used to treat melanoma, renal cell carcinoma, chronic myelogenous leukemia and hepatitis C.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.